KI
CPRX

Kula Investments’s Catalyst Pharmaceutical CPRX Stock Holding History

Kula Investments’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$340K Buy
+20,488
New +$338K 0.08% 424

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kula Investments's CPRX Position: Q1 2023 in Review

Kula Investments opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2023: 20,488 shares worth $340K. The stake represents 0.08% of the portfolio and ranks #424 among its holdings.

259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • Kula Investments held 20,488 shares of Catalyst Pharmaceutical worth $340K as of Q1 2023.
  • Catalyst Pharmaceutical was a new Kula Investments position in Q1 2023.
  • Catalyst Pharmaceutical made up 0.08% of Kula Investments's portfolio in Q1 2023, its #424 holding.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.